Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL): High Rates of Undetectable Minimal Residual Disease Remissions

Lipsky, A. H., Hill, B. T., Winter, A., Bachow, S. H., Viny, A. D., Rosenblat, T. L., Jurcic, J., & Lamanna, N. (2023). Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL): High Rates of Undetectable Minimal Residual Disease Remissions. Blood, 142(Supplement 1), 3274–3274. https://doi.org/10.1182/blood-2023-189718
Authors:
Andrew Lipsky
Brian T. Hill
Allison Winter
Spencer Henick Bachow
Aaron D. Viny
Todd Rosenblat
Joseph G. Jurcic
Nicole Lamanna
Affiliated Authors:
Andrew Lipsky
Aaron D. Viny
Todd Rosenblat
Joseph G. Jurcic
Nicole Lamanna
Columbia Affiliation:
Subjects:
Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia (OpenAlex Topic)
Epidemiology and Treatment of Childhood Leukemia (OpenAlex Topic)
Efficacy and Resistance in CML Treatment (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1182/blood-2023-189718
DOI:
10.1182/blood-2023-189718
Journal:
Blood
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: